Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Receivables (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Receivables for 5 consecutive years, with $26.1 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 40.89% to $26.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.1 million through Dec 2025, up 40.89% year-over-year, with the annual reading at $26.1 million for FY2025, 40.89% up from the prior year.
  • Receivables for Q4 2025 was $26.1 million at Rhythm Pharmaceuticals, down from $33.0 million in the prior quarter.
  • The five-year high for Receivables was $33.0 million in Q3 2025, with the low at $72.0 in Q1 2024.
  • Average Receivables over 5 years is $11.9 million, with a median of $13.8 million recorded in 2023.
  • Peak annual rise in Receivables hit 26446475.34% in 2024, while the deepest fall reached 100.0% in 2024.
  • Over 5 years, Receivables stood at $1.0 million in 2021, then tumbled by 99.99% to $80.0 in 2022, then skyrocketed by 18583650.0% to $14.9 million in 2023, then increased by 24.52% to $18.5 million in 2024, then surged by 40.89% to $26.1 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $26.1 million, $33.0 million, and $26.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.